For research use only. Not for therapeutic Use.
Retatrutide TFA（Cat No.:I041391）is a selective peptide-based therapeutic agent that targets specific receptors involved in metabolic regulation. It is designed to activate pathways that modulate insulin sensitivity and promote weight loss, making it a potential treatment for conditions like obesity and type 2 diabetes. The trifluoroacetate (TFA) salt form of Retatrutide enhances its stability, solubility, and bioavailability, facilitating its use in research and clinical trials. Studies are focused on evaluating its efficacy in improving metabolic health by influencing appetite regulation and fat metabolism, with promising results in early-stage trials.
| Purity | ≥95% |
| Target | Glucagon-Like Peptide 1 (GLP-1) Receptor |
